ArticleMedical microbiology and immunology2013
Performance evaluation of a new fourth-generation HIV combination antigen-antibody assay.
Article in Medical microbiology and immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Analytical and clinical performance evaluation of the Wantai chemiluminescence microparticle immunoassay on the Wan200 + analyzer for diagnosing HIV.Scientific reports · 2025Article
- Evaluation of a new human immunodeficiency virus antigen and antibody test using light-initiated chemiluminescent assay.Frontiers in cellular and infection microbiology · 2025Article
- Article
- Correlation between serology and nucleic acid amplification test in blood donors who are reactive for hepatitis B virus, hepatitis C and human immunodeficiency virus and evaluation of the epidemiological profile of infected people in blood centers in the State of Paraná.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2021Article
- Article
- The evaluation of low cut-off index values of ElecsysJournal of clinical laboratory analysis · 2020Article
- Analytical and Clinical Performance Evaluation of the Elecsys HIV combi PT Assay on the cobas e 602 Analyzer for the Diagnosis of Human Immunodeficiency Virus.American journal of clinical pathology · 2019Article
- A retrospective analysis of the application of the ElecsysJournal of clinical laboratory analysis · 2018Article
- Article
- Comparison of Elecsys Anti-HCV II Assay With Other HCV Screening Assays.Journal of clinical laboratory analysis · 2016Article
- Acute infections, cost and time to reporting of HIV test results in three U.S. State Public Health Laboratories.The Journal of infection · 2016Article
- Human Immunodeficiency Virus (HIV).Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2016Article
- Clinical application evaluation of two fourth-generation human immunodeficiency virus (HIV) screening assays in West China Hospital.Journal of clinical laboratory analysis · 2015Article
- Review
- Vaccination against infectious diseases: what is promising?Medical microbiology and immunology · 2014Review
- New automated chemiluminescence immunoassay for simultaneous but separate detection of human immunodeficiency virus antigens and antibodies.Journal of clinical microbiology · 2014Article
- Generation of a recombinant Gag virus-like-particle panel for the evaluation of p24 antigen detection by diagnostic HIV tests.PloS one · 2014Article
- Comparison: Imported and Indigenous HIV Fourth-generation immunodiagnostic kits.Asian journal of transfusion scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Education and diagnostic tests capable of early detection represent our most effective means of preventing transmission of human immunodeficiency virus (HIV). The importance of early detection is underlined by studies demonstrating increased life expectancy following early initiation of antiviral treatment. The Elecsys(®) HIV combi PT assay is a fourth-generation antigen-antibody combination assay developed to allow earlier detection of seroconversion, and to have increased sensitivity and improved specificity. We aimed to determine how early the assay could detect infection compared with existing assays; whether all HIV variants could be detected; and the assay's specificity using samples from blood donors, routine specimens, and patients with potential cross-reacting factors. Samples were identified as positive by the Elecsys(®) assay 4.9 days after a positive polymerase chain reaction result (as determined by the panel supplier), which was earlier than the 5.3-7.1 days observed with comparators. The analytical sensitivity of the Elecsys(®) HIV combi PT assay for the HIV-1 p24 antigen was 1.05 IU/mL, which compares favorably with the comparator assays. In addition, the Elecsys(®) assay identified all screened HIV subtypes and displayed greater sensitivity to HIV-2 homologous antigen and antibodies to HIV-1 E and O and HIV-2 than the other assays. Overall, the specificity of the Elecsys(®) assay was 99.88 % using samples from blood donors and 99.81 % when analyzing unselected samples. Potential cross-reacting factors did not interfere with assay performance. The Elecsys(®) HIV combi PT assay is a sensitive and specific assay that has been granted the CE mark according to Directive 2009/886/EC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.